A deep learning model can identify hospitalized patients at risk for hypoglycemia within 24 hours, according to a study published online June 11 in npj Digital ...
The triple combination regimen nearly doubled median progression free survival to 18.0 months compared with carfilzomib and dexamethasone alone in heavily pretreated patients.
About 31% of pediatric surgery patients receive an opioid prescription at discharge, according to a study published online June 23 in the Journal of the America ...
The ELSPIRE trial evaluated patients with PBC who had an inadequate response or intolerance to UDCA and baseline ALP levels between 1 to 1.67 x ULN.
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
In the phase 3 KEYNOTE-B15/EV-304 trial, perioperative pembrolizumab plus enfortumab vedotin reduced the risk of recurrence, progression, or death by 47% and improved overall survival by 35% over ...
Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.
More than one-third of the young adults surveyed (36%) reported that they seek out an urgent care clinic for nonemergency health issues, while 68% of older adults said they contact their primary care ...
Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.
The share of US adults taking GLP-1 medications to lose weight has reached a record 11%, a new Medicare program that began July 1 could drive that figure higher still.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results